{{위키데이터 속성 추적}}
{{Infobox medical condition (new)
| name            = 본태성혈소판증가증
| synonyms        = Essential thrombocythemia, Essential thrombocythaemia, essential thrombocytosis, primary thrombocytosis
| image           = Essential Thrombocythaemia.jpg
| caption         = 
| pronounce       = 
| field           = 
| symptoms        = 
| complications   = 
| onset           = 
| duration        = 
| types           = 
| causes          = 
| risks           = 
| diagnosis       = 
| differential    = 
| prevention      = 
| treatment       = 
| medication      = 
| prognosis       = 
| frequency       = 
| deaths          = 
}}
'''본태성혈소판증가증'''({{lang|en|essential thrombocytosis}}, {{lang|en|essential thrombocythaemia}}, {{lang|en|essential thrombocythemia}}, ET), '''본태성혈소판혈증'''(本態性血小板血症), '''특발성 혈소판 증가증'''({{lang|en|primary thrombocytosis}}), '''진성고혈소판증'''은 [[골수]] 내 [[거핵 세포]]로 인한 혈소판의 [[골수증식성질환|과생성]]을 특징으로 하는 희귀한 만성 혈액 질환이다.<ref name="path" /> [[급성 골수성 백혈병]]이나 [[골수섬유증]]으로 발전할 수 있다.<ref name="path" /> 4가지 [[골수증식성질환]] 가운데 하나이다.<ref name="path">{{저널 인용 |last1=Beer |first1=PA |last2=Green |first2=AR |title=Pathogenesis and management of essential thrombocythemia |journal=Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program |date=2009 |pages=621–8 |doi=10.1182/asheducation-2009.1.621 |pmid=20008247 |url=http://asheducationbook.hematologylibrary.org/content/2009/1/621.full.pdf |format=PDF}}</ref>

== 증상 ==
가장 흔한 증상으로는 출혈, [[혈전증]], 두통, 메스꺼움, 구토, 복통, 시각 장애, 어지러움, [[실신]], 손발의 저림이 있다. [[백혈구 증가증]], [[빈혈]], [[비종]]이 가장 흔한 징표이다.<ref name="paed">{{저널 인용 |last1=Fu |first1=R |last2=Zhang |first2=L |last3=Yang |first3=R |title=Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment |journal=British Journal of Haematology |date=November 2013 |volume=163 |issue=3 |pages=295–302 |doi=10.1111/bjh.12530 |pmid=24032343}}</ref><ref>{{저널 인용 |last1=Frewin |first1=R |last2=Dowson |first2=A |title=Headache in essential thrombocythaemia.|journal=International Journal of Clinical Practice |date=October 2012 |volume=66 |issue=10 |pages=976–83 |doi=10.1111/j.1742-1241.2012.02986.x |pmid=22889110 |url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469735/pdf/ijcp0066-0976.pdf |format=PDF |pmc=3469735}}</ref><ref>{{저널 인용 |last=Tefferi |first=A |title=Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. |journal=American Journal of Hematology |date=March 2011 |volume=86 |issue=3 |pages=292–301 |doi=10.1002/ajh.21946 |pmid=21351120}}</ref>

== 병인 ==
비정상 거핵세포에서 탄생한 혈소판들이 활성화되어 혈소판의 수를 증가시켜 혈전증의 가능성에 기여한다.<ref name="path2">{{저널 인용 |last=Vannucchi |first=AM |title=Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia |journal=Internal and Emergency Medicine |date=June 2010 |volume=5 |issue=3 |pages=177–84 |doi=10.1007/s11739-009-0319-3 |pmid=19789961}}</ref>

== 치료 ==
본태성혈소판증가증이 있다고 해서 반드시 치료가 필요한 것은 아니다.<ref name="man1">{{저널 인용 |last=Cervantes |first=F |title=Management of essential thrombocythemia. |journal=Hematology / the Education Program of the American ĺSociety of Hematology |date=2011 |volume=2011 |pages=215–21 |doi=10.1182/asheducation-2011.1.215 |pmid=22160037 |url=http://asheducationbook.hematologylibrary.org/content/2011/1/215.full.pdf |format=PDF}}</ref><ref name="man2">{{저널 인용 |last=Birgegård |first=G |title=Pharmacological management of essential thrombocythemia. |journal=Expert Opinion on Pharmacotherapy |date=July 2013 |volume=14 |issue=10 |pages=1295–306 |doi=10.1517/14656566.2013.797408 |pmid=23668666}}</ref><ref name="man3">{{저널 인용 |last1=Tefferi |first1=A |last2=Barbui |first2=T |title=Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. |journal=Leukemia |date=August 2013 |volume=27 |issue=8 |pages=1617–20 |doi=10.1038/leu.2013.99 |pmid=23558521 |url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740400/pdf/leu201399a.pdf |format=PDF |pmc=3740400}}</ref>

[[히드록시카바마이드]](hydroxycarbamide), [[인터페론α]], [[아나그렐리드]]가 혈소판의 수를 낮출 수 있다.

== 각주 ==
{{각주}}

== 외부 링크 ==
{{Medical resources
|  ICD10          = {{ICD10|D|75|2|d|70}}, {{ICD10|D|47|3|d|37}}
|  ICD9           = {{ICD9|238.71}}
|  ICDO           = {{ICDO|9962|3}}
|  OMIM           = 187950
|  DiseasesDB     = 4522
|  MedlinePlus    = 000543
|  eMedicineSubj  = med
|  eMedicineTopic = 2266
|  MeshID         = D013920
}}
* [http://www.pvreporter.com/ PV Reporter - Myeloproliferative Neoplasm Website, MPN Patient Research Hub]
{{질병}}
{{전거 통제}}
{{토막글|질병}}

[[분류:응고 병증]]
[[분류:골수성 신생물]]